- Home
- GSIW vs RDHL Comparison
GSIW vs RDHL Comparison
Compare GSIW & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GSIW | RDHL |
|---|---|---|
| Founded | 2016 | 2009 |
| Country | Hong Kong | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.9M | 3.9M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | GSIW | RDHL |
|---|---|---|
| Price | $0.15 | $1.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 357.8K | 71.8K |
| Earning Date | 01-01-0001 | 09-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $5,368,221.00 | ★ $9,550,000.00 |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 283.23 | 157.62 |
| 52 Week Low | $0.09 | $1.01 |
| 52 Week High | $1.79 | $8.06 |
Technical Indicators
Market Signals| Indicator | GSIW | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 48.08 | 50.83 |
| Support Level | $0.14 | $1.18 |
| Resistance Level | $0.15 | $1.26 |
| Average True Range (ATR) | 0.01 | 0.05 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 50.00 | 83.84 |
Price Performance
Historical ComparisonAbout GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong; and I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.